On April 28, 2021 Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, reported the acceptance of an abstract for a poster discussion presentation at the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Seven and Eight Biopharmaceuticals, APR 28, 2021, View Source [SID1234578631]). The abstract details additional interim safety and efficacy results for a phase 1 study of BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors (NCT03486301).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to share additional information about BDB001 in combination with pembrolizumab at the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting," said Dr. Robert H.I. Andtbacka, Chief Medical Officer, Seven and Eight Biopharma. "This builds upon the promising monotherapy data we reported on recently and helps illustrate the potential for BDB001 in combination with anti-PD-(L)1 therapies in difficult to treat tumors."
The ASCO (Free ASCO Whitepaper) Annual Meeting will be held virtually on June 4-8, 2021 and showcases innovative scientific research in clinical oncology and advancements in cancer therapy.
Details on Seven and Eight Biopharma’s poster discussion presentation:
Abstract Title: BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results.
Session Title: Poster Discussion Session, Developmental Therapeutics—Immunotherapy
On-Demand Session Release Date and Time: 6/4/2021, 9:00 AM-10:00 AM
Abstract Number for Publication: 2512
This year, ASCO (Free ASCO Whitepaper) reviewed more than 5,400 abstracts for the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting. More information about the meeting may be accessed at View Source According to ASCO (Free ASCO Whitepaper)’s Embargo Policy, abstracts will be released to the public on ASCO (Free ASCO Whitepaper)’s Meeting Library at 5:00 p.m. ET on May 19, 2021.